ADMETrix: ADMET-Driven De Novo Molecular Generation

02 June 2025, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

We introduce ADMETrix, a de novo drug design framework that combines the generative model REINVENT with ADMET AI, a geometric deep learning architecture for predicting pharmacokinetic and toxicity properties. To our knowledge, this is the first integration enabling real-time generation of small molecules optimized across multiple ADMET endpoints. We evaluate our method in two settings: (i) multi-parameter optimization of ADMET and physicochemical properties, and (ii) scaffold hopping to reduce toxicity while preserving key pharmacophoric features. Using the GuacaMol benchmark, we provide the first systematic evaluation of REINVENT in a multi-objective ADMET context, demonstrating its advantages in generating drug-like, biologically relevant molecules.

Keywords

De Novo Molecular Design
ADMET Optimization

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.